Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#3808 Comparison of [18F]AlF-NOTA-JR11 with [68Ga]DOTA-JR11 PET/MRI in models, mice, and neuroendocrine tumor patients

Introduction: Compared with [68]Ga, [18]F has the advantages of high production yield, shorter positron range, and favourable half-life allowing for centralized production and distribution to distant centers.

Conference:

Presenting Author: Yu J

Authors: Ding X, Meng X, Xie Q, Yu J,

Keywords: [18F]AlF-NOTA-JR11, [68Ga]DOTA-JR11, neuroendocrine tumor, PET/MRI,

#3685 Somatostatin receptor imaging with difference positive rate of mice

Introduction: Majority of neuroendocrine neoplasms express SSTR2, and the pathological results of a single lesion cannot accurately reflect the expression of SSTR2 in other lesions because of heterogeneity.

Conference:

Presenting Author:

Authors: Qing X, Xiangxi M, Zhi Y, Jiangyuan Y,

Keywords: neuroendocrine neoplasm, somatostatin receptor, imaging, immunohistochemistry,

#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O

Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Nicolas G, Baum R, Herrmann K, Lassmann M, Hicks R,

Keywords: PRRT, 177Lu, OPS201,